Differences in Tumor Doubling Time Between Clinical and Pathological Parameters in The Treatment of Lung Cancer Chemotherapy

Abstract

Background:   Lung cancer is malignant disease with relatively high incidence in the setting of organ cancer, characterized by rapid tumor growth, low grade of differentiation and low 5-year survival.

TDT has critical value in differentiating benign or active tumors with slow development. The shorter TDT means increase in rapid tumor development and thus decrease in survival. In the past, TDT has been used in many cases for both malignant screening and patient survival, but it is now  attempt to evaluate the antitumor effect. The Aim: We aimed to investigate the differences in tumor doubling time between the clinical and pathological parameters of chemotherapy for lung cancer. Patients and methods: Ninety-seven patients with lung cancer who were received standard chemotherapy  for indication. Patients with radiographic findings of lung tumors before and after treatment and who did not discontinue treatment were included. Treatment effect (CR; complete remission PR; partial remission PD; progression) after treatment was compared for several clinicopathological parameters such as lesion site, lesion size, histotype, and stage. The results and conclusions:  The difference in tumor doubling time between treatment effects in the chemotherapy treatment of lung cancer is as follows. Tumor doubling time was significantly shorter in central and peripheral lung cancers in the affected site, in the lesion size ~5.0 cm, in the histological type squamous cell carcinoma, in the stage IA-B and IIIA-B compared with the partial remission in the complete remission. Tumor doubling time was -19.8±2.1days for complete remission, -52.9±2.1days for partial remission and 48.9±2.2days for progression.